BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

MultiGEN Diagnostics Receives California License for Patient Testing


8/18/2009 4:58:03 PM

Cost effective solution for patient testing: Introducing comprehensive and affordable molecular diagnosis with verifiable accuracy.

San Diego, Calif., August 18, 2009 -- San Diego based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA sequencing technology (MultiGEN) for a wide range of clinical testing in molecular diagnostics. “Until now, lack of a single testing platform has resulted in fragmenting the diagnostic market, forcing laboratories to adopt number of alternative methods such as traditional culture, serology and probe based DNA testing,” says Dr.Moorthy, President and Founder of MultiGEN Diagnostics. “Present test methods have increased cost of testing, and hence all clinically relevant targets are not tested routinely. The use of a single reliable and versatile single platform technology (MultiGEN) for testing diverse clinical sample unifies testing procedures and reduces cost significantly. “MultiGEN’s unique features will exceed end-user expectations, and thereby encourage further use of molecular diagnostics in clinical markets,” says Dr. Moorthy.

MultiGEN’s patented platform technology allows detection and confirmation of multiple targets simultaneously using unmatched DNA sequencing, while still maintaining the highest possible sensitivity and specificity. These tests include- panels for common pathogens causing an infectious syndrome (e.g. STDs - sexually transmitted diseases), acquired mutations in cancer that affect the response to drugs (e.g. K-ras, EGFR mutations for colo-rectal cancer therapy), and genetic predisposition to disease (e.g. Thrombophilia panel with Factor V, Prothrombin, MTHFR for clotting disorders).

Dr. Roger Hodkinson, a clinical pathologist with MultiGEN Diagnostics comments, “MultiGEN is pioneering the concept of ‘Syndrome Driven’TM test panels for the simultaneous detection of multiple DNA targets”. He further adds, “The proprietary test platform has verifiable accuracy, and with its automated off-the-shelf liquid handling systems and genetic analyzers, it enables to decrease the hands-on technical time, minimize human error, and reduce the overall cost”. “MultiGEN Diagnostics accepts a variety of samples for its tests including buccal swabs, and the results are reported within a day. “This platform technology is flexible enough to launch new test menus within weeks, and detect ever changing microbial virulence, including H1N1, HIV, and MRSA,” says Dr. Linda Wasserman, Medical Director of MultiGen Diagnostics.

Contact : Dr.T.V.Moorthy
Telephone: (858 ) 523 1313
e-mail: info@multigen-diagnostics.com


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->